BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250512
DTEND;VALUE=DATE:20250515
DTSTAMP:20260515T094340
CREATED:20250225T112204Z
LAST-MODIFIED:20250225T112204Z
UID:40566-1747008000-1747267199@www.pharmajournalist.com
SUMMARY:4th ALS Drug Development Summit
DESCRIPTION:The ALS Drug Development Summit is the definitive industry-led forum dedicated to advancing breakthroughs in ALS therapeutics. With the field evolving rapidly\, recent milestones—such as Insitro’s AI-driven target discovery with Bristol Myers Squibb and Dewpoint Therapeutics’ collaboration with Mitsubishi Tanabe Pharma America on TDP-43 condensate modulators—highlight the momentum in novel drug discovery. Meanwhile\, QurAlis’ clinical trials for QRL-101 and QRL-201 and innovations in biomarker platforms are reshaping the treatment landscape. \nJoin 200+ scientific leaders in Boston to tackle key challenges in target validation\, biomarker development\, and clinical trial optimization—driving progress toward effective ALS and FTD therapies. \nTo know more visit: https://ter.li/48rlwg
URL:http://www.pharmajournalist.com/event/4th-als-drug-development-summit/
LOCATION:Revere\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250513
DTEND;VALUE=DATE:20250516
DTSTAMP:20260515T094340
CREATED:20250214T120932Z
LAST-MODIFIED:20250214T120932Z
UID:40492-1747094400-1747353599@www.pharmajournalist.com
SUMMARY:3rd Precision Medicine in Inflammatory Bowel Disease Summit
DESCRIPTION:Following a year of exceptional progress in IBD drug development\, fierce competition in clinical trials for Chron’s Disease and Ulcerative Colitis remains high\, and it’s time for biopharma to push the boundaries of efficacy and distinguish their therapies amongst the market. \nFeaturing three days of data-driven sessions from 25+ world-class speakers\, the 3rd Precision Medicine in Inflammatory Bowel Disease returns as the field’s most comprehensive learning and networking forum; dedicated to showcasing the latest data and advances in IBD therapeutic development. \nSee the full program here: https://ter.li/tjjok6 \nWith transformative advancements in disease understanding\, AI-powered biomarker development\, patient stratification\, and advanced monitoring techniques paving the way for a new era of precision IBD therapies\, join 80+ IBD specialists to: \n\nRefine models and proof-of-concept studies to reduce clinical trial failure rates and improve translational outcomes\nInnovate treatment pathways to optimize safety and efficacy\nMinimize adverse events while enhancing therapeutic synergies\nLeverage emerging therapeutic modalities to refine patient selection and optimize therapeutic outcomes\n\nWhen & Where: May 13-15\, 2025 | Boston\, MA \nWho: 80+ Precision Medicine\, Diagnostics\, Translational\, Clinical\, Computational Biology\, Gastrointestinal and Inflammation experts \nAgenda: https://ter.li/tjjok6
URL:http://www.pharmajournalist.com/event/3rd-precision-medicine-in-inflammatory-bowel-disease-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR